Leerink Partners analyst David Risinger has maintained their bullish stance on CNTA stock, giving a Buy rating on July 14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Buy rating due to a combination of factors that positively influence the perception of Centessa Pharmaceuticals. One of the key reasons is the promising development in the orexin agonist class, particularly highlighted by Takeda’s positive Phase 3 results for their orexin receptor 2-selective agonist, oveporexton. These results, which include an attractive safety profile and statistically significant improvements across symptoms, bolster confidence in similar future competitors such as Centessa’s ORX750.
Furthermore, the absence of serious treatment-related adverse events in Takeda’s trials, along with the high percentage of participants continuing into long-term studies, suggests a favorable outlook for the orexin agonist class. This development enhances the potential market positioning for Centessa Pharmaceuticals, making its stock an attractive investment opportunity. Risinger anticipates that these advancements will set a positive precedent for Centessa’s future endeavors in this therapeutic area.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and AbbVie. According to TipRanks, Risinger has an average return of 9.1% and a 54.27% success rate on recommended stocks.
In another report released on July 14, BMO Capital also maintained a Buy rating on the stock with a $35.00 price target.